<DOC>
	<DOCNO>NCT01354990</DOCNO>
	<brief_summary>The primary objective study obtain safety information use sitagliptin ( JANUVIA® ) endocrinologists , diabetologists , internist , general practitioner .</brief_summary>
	<brief_title>A Post Marketing Safety Study Sitagliptin ( JANUVIA® ) ( MK-0431-234 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Must take sitagliptin ( JANUVIA™ ) treatment type 2 diabetes mellitus Treating physician must agree provide information regard participant treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>